DE60106252D1 - Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren - Google Patents

Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren

Info

Publication number
DE60106252D1
DE60106252D1 DE60106252T DE60106252T DE60106252D1 DE 60106252 D1 DE60106252 D1 DE 60106252D1 DE 60106252 T DE60106252 T DE 60106252T DE 60106252 T DE60106252 T DE 60106252T DE 60106252 D1 DE60106252 D1 DE 60106252D1
Authority
DE
Germany
Prior art keywords
pyprolopyridinone
derivatives
substituted
phosphodiesterase inhibitors
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60106252T
Other languages
English (en)
Other versions
DE60106252T2 (de
Inventor
Zhihua Sui
J Macielag
Jihua Guan
Weiqin Jiang
C Lanter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of DE60106252D1 publication Critical patent/DE60106252D1/de
Application granted granted Critical
Publication of DE60106252T2 publication Critical patent/DE60106252T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE60106252T 2000-05-17 2001-05-03 Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren Expired - Lifetime DE60106252T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20464600P 2000-05-17 2000-05-17
US204646P 2000-05-17
PCT/US2001/014391 WO2001087882A2 (en) 2000-05-17 2001-05-03 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
DE60106252D1 true DE60106252D1 (de) 2004-11-11
DE60106252T2 DE60106252T2 (de) 2006-03-02

Family

ID=22758822

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60106252T Expired - Lifetime DE60106252T2 (de) 2000-05-17 2001-05-03 Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren

Country Status (29)

Country Link
US (3) US6635638B2 (de)
EP (1) EP1296981B1 (de)
JP (1) JP5366349B2 (de)
KR (2) KR20030031483A (de)
CN (1) CN1280291C (de)
AR (1) AR028575A1 (de)
AT (1) ATE278690T1 (de)
AU (1) AU6117801A (de)
BG (1) BG65925B1 (de)
CA (1) CA2409743C (de)
CZ (1) CZ20023945A3 (de)
DE (1) DE60106252T2 (de)
ES (1) ES2230316T3 (de)
GE (1) GEP20053510B (de)
HK (1) HK1054034B (de)
HR (1) HRP20020911B1 (de)
HU (1) HUP0302226A3 (de)
IL (2) IL152872A0 (de)
MX (1) MXPA02011425A (de)
MY (1) MY126917A (de)
NO (1) NO324843B1 (de)
NZ (1) NZ522732A (de)
PL (1) PL363150A1 (de)
PT (1) PT1296981E (de)
RU (1) RU2267490C2 (de)
SK (1) SK286992B6 (de)
UA (1) UA72611C2 (de)
WO (1) WO2001087882A2 (de)
ZA (1) ZA200210114B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
WO2002064591A2 (en) * 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
EP1360185B1 (de) 2001-02-12 2005-08-24 Lilly Icos LLC Carbolinderivate
DK1448562T3 (da) 2001-11-14 2007-09-24 Ortho Mcneil Pharmaceutical Co Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
EP1534707B9 (de) * 2002-06-19 2008-11-26 Janssen Pharmaceutica N.V. SUBSTITUIERTE 2,4-DIHYDROPYRROLOç3,4B]CHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
US7045652B2 (en) * 2002-07-03 2006-05-16 Pfizer Inc Processes for preparing substituted aryl boronic acids
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EP1737461B1 (de) 2004-03-15 2012-12-12 PTC Therapeutics, Inc. Carbolin-derivate zur hemmung der angiogenese
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
EP1851227A4 (de) * 2005-02-25 2010-03-10 Janssen Pharmaceutica Nv Effizientes und stereoselektives verfahren zur massensynthese von 3-(r)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo{3,4-b}chinolin-9-on
WO2006093719A1 (en) * 2005-02-25 2006-09-08 Janssen Pharmaceutica, N.V. An efficient and stereoselective process for large scale synthesis of 3-(r)-3- (2,3-dihydrobenzofuran-5-yl)-1,2,3,4- tetrahydropyrrolo{3,4-b}quinolin-9-one
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (de) 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2379076B1 (de) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase-hemmer und ihre verwendungen
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
KR101236188B1 (ko) * 2011-03-10 2013-02-22 한국화학연구원 신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
WO2013043553A1 (en) * 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN107216327A (zh) * 2017-06-27 2017-09-29 山东大学 5型磷酸二酯酶抑制剂及其制备方法和用途
CN108752340B (zh) * 2018-07-18 2020-09-01 山东中医药大学附属医院 吡咯并喹啉衍生物及其在治疗心律失常中的用途
CN109134463B (zh) * 2018-09-17 2020-05-08 山东大学 β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US204646A (en) * 1878-06-04 Improvement in hat-brims
DE2023514A1 (de) 1970-05-14 1971-12-02 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 5,6-gamma-Pyridonderivaten
CH625521A5 (de) 1976-10-15 1981-09-30 Sandoz Ag
US5116840A (en) 1985-06-13 1992-05-26 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
ATE224377T1 (de) 1994-04-29 2002-10-15 Takeda Chemical Industries Ltd Kondensierte heterocyclische verbindung, deren herstellung und verwendung als gnrh antagonisten
DE4436509A1 (de) * 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
US5866567A (en) 1995-06-01 1999-02-02 Takeda Chemical Industries, Ltd. Diazepinones, their production and use
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
FR2792937B1 (fr) * 1999-04-27 2001-08-10 Cemaf NOUVEAUX DERIVES DE PYRROLO-(3,4-b) QUINOLEINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION A TITRE DE MEDICAMENT
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази

Also Published As

Publication number Publication date
EP1296981B1 (de) 2004-10-06
HRP20020911B1 (en) 2009-01-31
HUP0302226A3 (en) 2012-12-28
SK286992B6 (sk) 2009-09-07
NO20025525L (no) 2003-01-03
KR100854050B1 (ko) 2008-08-26
UA72611C2 (uk) 2005-03-15
BG65925B1 (bg) 2010-05-31
GEP20053510B (en) 2005-05-10
HK1054034B (zh) 2005-04-29
JP2003533524A (ja) 2003-11-11
ES2230316T3 (es) 2005-05-01
BG107284A (bg) 2003-07-31
ZA200210114B (en) 2004-03-12
KR20030031483A (ko) 2003-04-21
US20020010183A1 (en) 2002-01-24
US20040044021A1 (en) 2004-03-04
RU2267490C2 (ru) 2006-01-10
SK17132002A3 (sk) 2003-12-02
KR20020094063A (ko) 2002-12-16
NZ522732A (en) 2004-10-29
US6635638B2 (en) 2003-10-21
CZ20023945A3 (cs) 2003-10-15
PL363150A1 (en) 2004-11-15
US6818646B2 (en) 2004-11-16
JP5366349B2 (ja) 2013-12-11
EP1296981A2 (de) 2003-04-02
WO2001087882A2 (en) 2001-11-22
IL152872A (en) 2010-11-30
DE60106252T2 (de) 2006-03-02
CN1280291C (zh) 2006-10-18
IL152872A0 (en) 2003-06-24
HRP20020911A2 (en) 2004-12-31
NO324843B1 (no) 2007-12-17
HUP0302226A2 (hu) 2003-11-28
HK1054034A1 (en) 2003-11-14
WO2001087882A3 (en) 2002-05-23
CA2409743A1 (en) 2001-11-22
AR028575A1 (es) 2003-05-14
ATE278690T1 (de) 2004-10-15
AU6117801A (en) 2001-11-26
MY126917A (en) 2006-10-31
CA2409743C (en) 2010-10-19
MXPA02011425A (es) 2004-09-06
CN1441801A (zh) 2003-09-10
US20050113402A1 (en) 2005-05-26
NO20025525D0 (no) 2002-11-18
PT1296981E (pt) 2004-12-31

Similar Documents

Publication Publication Date Title
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
DK1319003T3 (da) Xanthin-phosphodiesterase V-inhibitorer
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
ATE339403T1 (de) Pyrrolderivate als phosphodiesterase vii-hemmer
DE50107316D1 (de) Neue substituierte imidazotriazinone als pde ii-inhibitoren
ATE236157T1 (de) Imidazopyridinderivate als phosphodiesterase vii- hemmer
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE414056T1 (de) Substituierte c-cyclohexylmethylamin-derivative
ATE300945T1 (de) Isoxazolderivate als phosphodiesterase vii-hemmer
DK1322592T3 (da) Substituerede 1-aminobutan-3-ol-derivater
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
ATE247121T1 (de) Imidazolderivate als phosphodiesterase vii-hemmer
DE60118941D1 (de) Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren
DE50112454D1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN